Lipigon Pharmaceuticals (LPGO) Q2 2025 earnings summary

Executive summary

• Last patient enrolled in the phase II clinical trial for Lipisense®; follow-up period initiated and preliminary results expected by end of 2025.

• Strengthened financial position through a fully guaranteed rights issue, raising approximately SEK 37.4 million before costs.

• Continued business development focus and increased industry visibility planned for autumn.

Financial highlights

• Net sales for Q2 2025 and H1 2025 were SEK 0 thousand, compared to SEK 8,970 thousand in the same periods last year, due to a prior milestone payment.

• Operating loss for Q2 2025 was SEK -8,486 thousand (Q2 2024: -357 thousand); H1 2025 loss was SEK -17,551 thousand (H1 2024: -7,771 thousand).

• Result per share for H1 2025 was SEK -0.05 (H1 2024: -0.06).

• Cash and cash equivalents at June 30, 2025, were SEK 24,986 thousand (June 30, 2024: 19,477 thousand).

Outlook and guidance

• Preliminary results from the phase II Lipisense® study are expected by the end of 2025.

• Business development and industry engagement will be intensified ahead of study results.